Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio, Inc. (NYSEA:IBIO) announces the immediate resignation of CEO Thomas F. Isett from both the Board of Directors and his executive duties. The current Chair, William (Chip) Clark, will oversee the leadership team during the search for a new CEO. Isett's contributions included enhancing iBio's portfolio and acquiring RubrYc’s drug discovery engine. The company emphasizes its commitment to developing innovative antibody treatments and maintaining its operations amidst leadership changes.
iBio, Inc. (NYSEA:IBIO) is divesting its contract development and manufacturing organization (CDMO) to focus on immuno-oncology assets and AI-driven drug discovery. This restructuring is expected to yield approximately 50% in annualized cost savings, reducing monthly expenses by $2.5-3.0 million. The divestiture process is aimed at advancing lead candidates like IBIO-101 and optimizing their proprietary technology, with expectations to complete the sale in 2023, contributing to a cash runway into mid-2024.
iBio has provided its preliminary unaudited financial results for the fiscal year ending June 30, 2022, reporting revenues of approximately $2.4 million, a slight increase of 1% from fiscal 2021. The company recorded a net loss of $50.3 million, expanding by $27.1 million due to rising R&D and administrative expenses. In a strategic move, iBio acquired assets from RubrYc Therapeutics, enhancing its immunotherapy portfolio. However, it has opted not to proceed with the IND submission for its COVID-19 vaccine candidate IBIO-202.
iBio announced the acquisition of RubrYc Therapeutics to enhance its immuno-oncology pipeline and AI-driven drug discovery capabilities. The acquisition includes a patented AI Drug Discovery Platform and rights to two previously licensed drug candidates, with an upfront payment of $1 million in stock. Potential development milestones of up to $5 million are also available. iBio aims to extend its cash runway and will discuss its strategic transformation and FY2022 results in a conference call on September 27, 2022.
iBio, Inc. announced successful completion of its first batch of a proprietary nucleocapsid antigen for the vaccine candidate IBIO-202 under cGMP conditions. This new vaccine aims to provide long-lasting protection against COVID-19 variants through the nucleocapsid protein, rather than the spike protein used in current vaccines. The company is analyzing data from its challenge studies to further validate this approach. iBio is actively pursuing funding opportunities with Congress to support next-generation COVID-19 vaccine development.
iBio, Inc. (NYSEA:IBIO) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company is known for its innovative FastPharming® Manufacturing System for biopharmaceuticals. A pre-recorded presentation will be available on demand for registered attendees starting May 24, 2022, and can also be accessed on iBio's website under 'News & Events'. iBio focuses on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases, leveraging its state-of-the-art manufacturing capabilities.
iBio, Inc. (NYSEA:IBIO) reported significant growth in revenue for Q3 FY2022, totaling approximately $1.9 million, up 154% from the previous year. The company is progressing towards clinical-stage status, with plans for its COVID-19 vaccine and the IL-2-sparing anti-CD25 antibody IBIO-101. Despite an increase in R&D and G&A expenses, leading to a net loss of $12.4 million, iBio maintains adequate cash reserves of approximately $48.6 million to support operations until September 2023. A special meeting for shareholders to approve a reverse stock split is forthcoming.
iBio, Inc. presented preclinical data on its monoclonal antibody candidate, IBIO-101, at the Frontiers in Cancer Immunotherapy 2022 conference. The research showed that IBIO-101, utilizing iBio's FastPharming and Glycaneering technologies, matched the efficacy of a traditional anti-CD25 antibody while enhancing effector function. The company plans to advance this anti-CD25 monoclonal antibody into clinical trials next year.
iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2022 third quarter financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing a detailed corporate update. The company specializes in next-generation biopharmaceuticals and sustainable, plant-based manufacturing through its FastPharming System. It focuses on developing treatments for cancers, fibrotic, and infectious diseases, along with offering contract development and manufacturing services.
iBio (NYSE:IBIO) announced its participation in the 18th Annual Protein & Antibody Engineering Summit in Boston from May 2-5, 2022. The company will showcase research demonstrating that its FastPharming Manufacturing System produces monoclonal antibodies with a uniform G0 glycosylation pattern, unlike traditional CHO cell culture methods, which yield more heterogeneous patterns. The presentation aims to illustrate the efficacy, rapid scalability, and potential time savings in achieving in vivo proof-of-concept for therapeutic applications.